Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.

Inclusion Criteria: * Voluntary informed consent. * Infertile female subjects indicated for egg donor programme in the context of ART. * Subjects aged ≥ 18 to ≤ 45 years at screening. * Body mass index (BMI) ≥ 18.0 and \< 30.0 kg/m2. * Normal results of a 2-dimensional (2D) or 3-dimensional (3D) transvaginal US (TVUS) at screening. * Planned transfer of a fresh single blastocyst from a donated egg. * Good quality sperm. * Planned endometrial preparation and luteal support. Exclusion Criteria: * History of two or more failed in-vitro fertilisation (IVF) / intra-cytoplasmic sperm injection (ICSI) cycles after embryo transfer of donor oocyte during the last attempts prior to the trial. * Gynaecological abnormality relevant to the ART procedure and outcome, which in the opinion of the investigator could interfere with the trial objectives. * Abnormal haemorrhage of the reproductive tract of undetermined origin. * Endometrial biopsy or endometrial local injury within one month prior to screening. * Diagnosis of severe endometriosis and/or adenomyosis. * Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results. * Relevant clinically significant abnormality in the results of safety laboratory tests at screening. * Systemic disease which might interfere with the purpose of the trial. * Any malignant neoplasm. * Known history of venous thrombosis or thromboembolism, including any coagulation abnormality leading to an increased risk of…